Early strong opiod treatment in cancer pain -Morphine vs weak opiods - ESOT-M

Dipartimento Integrato di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio0 个研究点开始时间: 2012年2月28日最近更新: 2015年2月2日

适应症

试验速览

暂无简介。

•Age >=18 years, both male and female • Patients with (solid or hematologic) cancer, at any stage of the disease • Patients able to take oral medications • Patients with mild-moderate average daily pain during the previous 24 hours, ie between 3 and 7 measured using a Numerical Rating Scale (NRS) to 11 levels (0-10) • Opioid-naïve patients, ie patients who at inclusion in the study are not receiving opioid analgesics or who do not receive chronic opioid analgesics around the clock • Patients with life expectancy greater than 3 months • Patients with good performance status (Karnofsky = 60) • Patients who, in the opinion of the clinician, ensure ''compliance'' to the protocol for cognitive performace and lack of psychiatric illness • Patients who give written informed consent for participation
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Chronic renal failure, grade 4 or 5 • Severe hepatic impairment • Severe respiratory insufficiency • Patients with malabsorption syndrome • Patients with diarrhea and/or nausea and vomiting due to specific cancer treatments • Patients with sub-ileus or bowel obstruction for whom oral opioids are not indicated • Contraindications to the use of any type of opioid drugs • Patients at inclusion are following a course of radiotherapy or radioiodine therapy to obtain pain relief, or for whom such treatment was completed less than 14 days or is planned in the next 4 weeks • Inclusion in other experimental studies

发起方

Dipartimento Integrato di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio